NP781880.RAYxpiAIWXivImG-yJq9PRGEltwg-wvg4iT-uuR2WgPak
has assertion: NP781880.RAYxpiAIWXivImG-yJq9PRGEltwg-wvg4iT-uuR2WgPak130 assertion
has provenance: NP781880.RAYxpiAIWXivImG-yJq9PRGEltwg-wvg4iT-uuR2WgPak130 provenance
has publication info: NP781880.RAYxpiAIWXivImG-yJq9PRGEltwg-wvg4iT-uuR2WgPak130 publicationInfo
type: Nanopublication
created: 2016-05-13T12:47:39+02:00
rights: http://opendatacommons.org/licenses/odbl/1.0/
rights holder: IBIGroup
subject: SIO_000983
used data: disgenetv3.0rdf
authored by: http://orcid.org/0000-0001-5999-6269
authored by: http://orcid.org/0000-0002-7534-7661
authored by: 0000-0002-9383-528X
authored by: http://orcid.org/0000-0003-0169-8159
authored by: http://orcid.org/0000-0003-1244-7654
created by: http://orcid.org/0000-0003-0169-8159
version: v4.0.0.0

NP781880.RAYxpiAIWXivImG-yJq9PRGEltwg-wvg4iT-uuR2WgPak130 assertion
type: Assertion
description: [Targeted therapies in the form of monoclonal antibodies directed against the endothelial growth factor receptor or the vascular endothelial growth factor have met with success, and have demonstrated the advantages of molecularly targeted therapy in colorectal cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine.
evidence: DisGeNET evidence - LITERATURE
SIO_000772: http://identifiers.org/pubmed/20015264
was generated by: ECO_0000203

befree-2016
imported on: 2016-02-19

DisGeNET evidence - LITERATURE
type: ECO_0000212
comment: Gene-disease associations inferred from text-mining the literature.

disgenetv3.0rdf
version: v4.0.0